# Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary Cancers

> **NCT03162510** · PHASE1 · COMPLETED · sponsor: **National Health Research Institutes, Taiwan** · enrollment: 18 (actual)

## Conditions studied

- Gastric Cancer in Situ
- Pancreatic Cancers
- Biliary Cancers

## Interventions

- **DRUG:** Oxaliplatin
- **DRUG:** Albumin-Bound Paclitaxel /nab-Paclitaxel
- **DRUG:** S-1
- **DRUG:** LV

## Key facts

- **NCT ID:** NCT03162510
- **Lead sponsor:** National Health Research Institutes, Taiwan
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-26
- **Primary completion:** 2021-06-07
- **Final completion:** 2022-01-31
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2022-04-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03162510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03162510, "Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary Cancers". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03162510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*